GSK Reports Headline Data from P-II Study of Seasonal Influenza mRNA Vaccine
Shots:
- The P-II trial evaluated the reactogenicity, safety & immunogenicity of a multivalent vaccine targeting all 3 WHO-recommended influenza strains in healthy young (n=250, 18-64yrs.) & older adults (n=250, 65-85yrs.)
- Study reached its pre-defined success criteria, showing acceptable safety & reactogenicity plus verifying mRNA platform’s ability of producing strong overall antibody titres. Based on this data, GSK will advance its mRNA seasonal influenza vaccine into P-III
- In addition, GSK secured partnership with CureVac for developing & manufacturing influenza and COVID-19 vaccines. It is enhancing its mRNA capabilities through investments in AI/ML-based sequence optimization, nanoparticle design & manufacturing
Ref: GSK | Image: GSK
Related News:- Merck Animal Health’s Nobivac NXT Canine Flu H3N2 Receives the USDA’s Approval for Canine Influenza
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
